| Proposal number
|
Sponsor/Funder
|
Title
|
Lead researcher
|
|
|
611
|
GSK
|
Long-acting beta2-agonists for chronic obstructive pulmonary disease
|
Kayleigh Kew
|
Further Details
|
|
628
|
GSK
|
Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib
|
Arnoud J. Templeton, MD
|
Further Details
|
|
631
|
GSK
|
Predictors of BPH Progression
|
Dr. Stephen Freedland, MD
|
Further Details
|
|
637
|
GSK
|
Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial
|
Sripal Bangalore
|
Further Details
|
|
639
|
GSK
|
Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease
|
Saurav Chatterjee MD
|
Further Details
|
|
645
|
GSK
|
The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension
|
Partha Sardar
|
Further Details
|
|
646
|
GSK
|
Factors influencing immune response and patient outcomes following influenza vaccination.
|
Dr Subhadra Rajanaidu
|
Further Details
|
|
647
|
GSK
|
Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials
|
David M. Kent, MD, MSc
|
Further Details
|
|
651
|
GSK
|
Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.
|
Thomas Verstraeten
|
Further Details
|
|
653
|
GSK
|
Functional Estimation of Interventional Effects
|
Joon Park
|
Further Details
|
Just a moment, the page is loading...